Viatris to Acquire Pacira for $1.65 Billion in Non-Opioid Pain Push; Hengrui's Fluzoparib EMA Application Accepted

In the high-stakes world of pharmaceutical mergers and acquisitions, Viatris Inc. just made a calculated bet that the future of pain management lies far from opioids. The company announced Wednesday it will acquire Pacira BioSciences Inc. for $1.65 billion in cash—a move that signals how traditional drugmakers are racing to corner the market on non-addictive alternatives.

The deal values Pacira at $36.50 per share, a 44.8% premium over its recent trading price. What Viatris gets is immediate access to two established, patent-protected products: EXPAREL for post-surgical acute pain and ZILRETTA for knee osteoarthritis. Together, these drugs generated roughly $746 million in revenue over the past 12 months. The transaction, expected to close by late 2026, positions Viatris as a self-proclaimed leader in the non-opioid pain space.

The timing is no accident. As regulatory pressure on opioids intensifies and healthcare systems grapple with addiction crises, branded specialty drugs with built-in safety narratives have become the new growth engines for companies facing generic competition. Viatris, armed with excess cash and short-term borrowing capacity, is using minimal leverage to absorb a proven cash-flow asset. It's a playbook increasingly familiar across the industry.

Meanwhile, halfway across the world, another pharmaceutical story is unfolding—one that underscores how Chinese drugmakers are expanding their regulatory ambitions beyond domestic borders.

Jiangsu Hengrui Pharmaceuticals Co., Ltd., China's largest homegrown pharma company by market capitalization, announced Thursday that the European Medicines Agency has accepted its marketing authorization application for fluzoparib. The drug, a PARP inhibitor, is being sought for use in combination with abiraterone to treat adult patients with metastatic castration-resistant prostate cancer (mCRPC).

This marks the second self-developed innovative drug Hengrui has submitted for EU approval, a milestone that reflects the company's growing confidence in navigating European regulatory pathways. The application rests on data from the international, multi-center Phase III FUZUPRO study, which demonstrated a statistically significant improvement in radiographic progression-free survival. Patients receiving fluzoparib plus abiraterone achieved a median rPFS of 24.8 months compared to 19.9 months in the control group, with a hazard ratio of 0.71.

Fluzoparib is already China's first domestically approved PARP inhibitor, with five indications cleared for use at home. But the EMA acceptance signals something more strategic: Hengrui is no longer content to rely solely on the U.S. Food and Drug Administration as its gateway to global markets. The company is building parallel registration capabilities in Europe, a move that could directly enhance the value of its overseas intellectual property rights and set a template for future pipeline launches.

Hengrui isn't the only Chinese company making waves this week.

On October 8, Defand Therapeutics, a Hangzhou-based biotech founded just three years ago, announced a research collaboration and licensing agreement with Roche. The deal focuses on discovering and developing novel molecular glue degraders (MGDs) across multiple oncology and immunology targets. Defand will leverage its proprietary DEFUSE high-throughput screening platform for early-stage candidate discovery, with Roche taking over preclinical and clinical development—and securing global exclusive commercialization rights—once projects reach agreed-upon milestones.

According to reports from STAT and Endpoints, the total potential value of the deal, including upfront payments and milestones, approaches $1 billion. What Roche is buying isn't a finished product—Defand has yet to advance any molecule into Investigational New Drug applications—but rather a sustained capacity to generate novel molecules. The value of China's new molecular types, it seems, is shifting from the clinical stage to the discovery stage.

This is Roche's fourth deal in China since August 28, following agreements with Yingern for antibody-drug conjugates, Simcere for trispecific antibodies, and Earendil for bispecific antibodies. The pattern is clear: the Swiss pharma giant is betting on Chinese platforms and early-stage projects, not late-stage assets.

Back at Hengrui, the company's HER2 antibody-drug conjugate, SHR-A1811, also known as trastuzumab deruxtecan in its recombinant form, is poised for priority review in China. The National Medical Products Administration's Center for Drug Evaluation posted on October 9 that the drug is being considered for priority review for first-line treatment of locally advanced or metastatic HER2-positive breast cancer, either alone or in combination with pertuzumab.

This would be the fifth indication to enter priority review for SHR-A1811. On August 31, the Phase III SHR-A1811-307 study met its primary endpoint in a pre-specified interim analysis, demonstrating statistically significant improvements in progression-free survival compared to the standard THP regimen. The drug is already China's first domestically approved HER2 ADC, with existing indications in non-small cell lung cancer, HER2-positive breast cancer, and HER2-positive colorectal cancer.

The dense indication matrix is no accident. Each priority review filing expands SHR-A1811's addressable market, particularly in breast cancer, where comprehensive lifecycle coverage could significantly lift peak sales expectations. For Hengrui, it's also a demonstration of the global competitiveness of its ADC platform.

In the broader biotech capital markets, the week offered a cautionary tale.

TRex Bio Inc., an early-stage biotech focused on autoimmune and inflammatory diseases, priced its initial public offering on the low end of its range. The company sold approximately 8.33 million shares at $14 per share—below the indicated $14 to $16 range—raising roughly $116.7 million. Trading under the ticker TRXB on the Nasdaq Global Select Market beginning October 9, the offering reflects the stark bifurcation in the U.S. biotech IPO market.

While overall U.S. biotech IPO fundraising in 2026 has approached six times the level of the same period last year, the gains are concentrated in platform companies with multiple pipelines and near-term catalysts. Single-asset companies with key data readouts more than 18 months away are struggling to command premiums, and many are breaking issue price. TRex fits the latter profile: its lead candidate TRB-061, a tissue Treg modulator, is in Phase I trials for moderate-to-severe atopic dermatitis, with top-line data expected in mid-2027. A second candidate, TRB-071, targeting the IL-2/IL-15 pathway for inflammatory bowel disease, is slated to begin Phase I in the first half of 2027.

Eli Lilly and Company, the company's largest strategic investor, holds approximately 16.8% of shares post-IPO and has signaled plans to increase its stake to 19.9%. But even Lilly's backing wasn't enough to secure pricing above the range floor.

In late-stage clinical developments, Bristol-Myers Squibb Co. reported positive topline results from the Phase III EXCALIBER-RRMM study. The oral cereblon E3 ligase modulator iberdomide, when combined with daratumumab and dexamethasone, met its primary endpoint of progression-free survival in patients with relapsed or refractory multiple myeloma.

With a median follow-up of 23 months, the combination arm achieved a median PFS of 42 months compared to 20 months in the control group, representing a 51% reduction in the risk of progression or death (hazard ratio 0.49, p<0.000001). The study enrolled 800 patients who had received one to two prior lines of therapy. A secondary endpoint, minimal residual disease-negative complete response, also favored the iberdomide arm.

The results support accelerated FDA approval, with complete data to be presented at the American Society of Hematology annual meeting. For BMS, iberdomide represents a next-generation CELMoD—a newer class of immunomodulatory drugs—poised to rapidly displace traditional IMiDs in both first-line and relapsed multiple myeloma settings.

In regulatory news, the FDA approved Roche's Tecentriq (atezolizumab) in combination with chemotherapy for the adjuvant treatment of Stage III mismatch repair-deficient colon cancer. The approval, announced October 9, aligns with the PDUFA target date and establishes an immunotherapy-centric adjuvant regimen for a subset of locally advanced colon cancer patients with historically poor prognosis.

The dMMR subgroup is emerging as the population where immunotherapy first establishes standard-of-care in colorectal cancer adjuvant treatment. For Roche, it extends Tecentriq's footprint across both adjuvant and neoadjuvant settings in gastrointestinal tumors, reflecting how perioperative immunotherapy competition has expanded from lung and bladder cancers into colorectal indications.

Vir Biotechnology Inc. also scored a regulatory win. On October 9, the FDA granted fast track designation to VIR-5500, a PSMA-targeted T-cell engager, for the treatment of advanced metastatic castration-resistant prostate cancer. The drug works by simultaneously recognizing PSMA-positive tumor cells and T cells, directing immune effector cells toward prostate cancer. The indication targets patients who have failed standard therapies.

mCRPC remains the final battleground in prostate cancer treatment. PSMA-targeted radioligands like Novartis AG's Pluvicto have already reshaped the landscape, but T-cell engagers represent an alternative technical approach. Vir, leveraging its infectious disease platform for oncology immunotherapy, is accelerating VIR-5500's development. How it will fare against—or in sequence with—PSMA radioligand therapy remains an open question.

Finally, in a deal that marks the first regional collaboration for extracellular protein degraders, Ono Pharmaceutical Co., Ltd. has licensed Biohaven Ltd.'s MoDE pan-IgG degrader portfolio for Japan, South Korea, Taiwan, and ASEAN countries.

Ono paid an $80 million upfront payment, with an additional $20 million in near-term milestones and approximately 20% in sales royalties. The portfolio includes BHV-1300, BHV-1310, and BHV-1320. BHV-1300, the lead asset, is a first-in-class extracellular IgG degrader in Phase III trials for Graves' disease, capable of selectively clearing pathogenic IgG1, IgG2, and IgG4 autoantibodies. Biohaven retains U.S., European, and Chinese rights.

For Biohaven, the deal locks in non-dilutive funding for its MoDE platform without sacrificing equity, while preserving access to core markets. For Ono, the portfolio bolsters its late-stage autoimmune and inflammation pipeline. The collaboration signals how degrader technology is expanding beyond intracellular target proteins—like PROTACs and molecular glues—into peripheral circulation IgG, opening a new front in autoimmune therapy.

From non-opioid painkillers to IgG degraders, the week's deals reveal a common thread: pharmaceutical companies are increasingly betting on precision over breadth, targeting specific mechanisms and patient populations where they can establish clear clinical and commercial advantages. Whether these bets pay off will depend on execution, regulatory timing, and the ever-present uncertainty of clinical data. But the direction is unmistakable.